• 1.四川大學(xué)華西醫(yī)院普外科（成都610041）;;
  • 2.四川大學(xué)華西醫(yī)學(xué)中心腫瘤研究所(成都610041);

目的建立人肝細(xì)胞癌多藥耐藥亞株并對(duì)其主要特征進(jìn)行研究。方法應(yīng)用SMMC7721細(xì)胞株，通過(guò)不斷提高培養(yǎng)液中阿霉素（ADM）的濃度，長(zhǎng)期篩選培養(yǎng)，得到了人肝細(xì)胞癌多藥耐藥亞株SMMC7721/ADM后，對(duì)其特征進(jìn)行研究。結(jié)果①SMMC7721/ADM對(duì)ADM的抗藥性提高了33.3倍，對(duì)長(zhǎng)春新堿的抗藥性提高了16.8倍，對(duì)順鉑的抗藥性提高了2.8倍； ②耐藥細(xì)胞與親代細(xì)胞的生長(zhǎng)速度基本相同，倍增時(shí)間分別為32.0 h和30.5 h，呈現(xiàn)相似的生長(zhǎng)曲線； ③利用掃描和透射電鏡發(fā)現(xiàn)，耐藥細(xì)胞與親代細(xì)胞形態(tài)上的明顯差別是前者微絨毛變得粗短、稀疏、分布不均； ④耐藥細(xì)胞保持著肝細(xì)胞癌的特征，能在裸小鼠皮下移植再現(xiàn)； ⑤SMMC7721/ADM在去藥培養(yǎng)1個(gè)月和2個(gè)月后耐藥指數(shù)下降為28.0%和9.2%，而在ADM(0.04 μg/ml)存在下生長(zhǎng)2個(gè)月后，耐藥倍數(shù)可保持穩(wěn)定(35.4倍)。結(jié)論SMMC7721/ADM細(xì)胞亞株具有穩(wěn)定的耐藥性細(xì)胞株的基本特征。

引用本文： 智星,嚴(yán)律南,林萍,林琦遠(yuǎn). 人肝細(xì)胞癌耐阿霉素細(xì)胞亞株SMMC7721/ADM的誘導(dǎo)及其特征研究△. 中國(guó)普外基礎(chǔ)與臨床雜志, 2004, 11(3): 219-221. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Shiraga K, Sakaguchi K, Senoh T, et al. Modulation of doxorubicin sensitivity by cyclosporine A in hepatocellular carcinoma cells and their doxorubicinresistant sublines [Ｊ]. J Gastroenterol Hepatol, 2001; 16(4)∶460.
2. 程國(guó)鈞, 李亞里, 田方， 等. 不同方式誘導(dǎo)人卵巢癌順鉑耐藥細(xì)胞株的比較 [Ｊ]. 中華腫瘤雜志, 2001; 23（4）∶305.
3. 陸家齊, 陸連榮, 蔣彥和, 等. PdGC81 人體胃底分化腺癌細(xì)胞系的建立及其生物學(xué)特征的觀察 [Ｊ]. 中華腫瘤雜志, 1986； 8（1）∶4.
4. 趙憲琪. 乳腺癌細(xì)胞系的建立與應(yīng)用研究 [Ｊ]. 實(shí)用腫瘤學(xué)雜志, 2001; 15（3）∶239.
5. Chauffert B, Martin M, Hammann A, et al. Amiodaroneinduced enhancement of doxorubicin and 4’deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo [Ｊ]. Cancer Res, 1986; 46(2)∶825.
6. Twentyman PR, Fox NE, Wright KA, et al. Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells [Ｊ]. Br J Cancer, 1986; 53(4)∶529.
7. 梁永鋸， 周肵熙， 潘啟超， 等. 肝癌體外藥敏感性試驗(yàn) [Ｊ]. 腫瘤, 2001; 21（1）∶17.
8. Flens MJ, Zaman GJ, van der Valk P, et al. Tissue distribution of the multidrug resistance protein [Ｊ]. Am J Pathol, 1996; 148(4)∶1237.
9. McGovern F, Kachel T, Vijan S, et al. Establishment and characterization of a doxorubicinresistant human bladder cancer cell line (MGHU1R) [Ｊ]. J Urol, 1988; 140(2)∶410.
10. Keizer HG, Schuurhuis GJ, Broxterman HJ, et al. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased Pglycoprotein expression in cultured SW1573 human lung tumor cells [Ｊ]. Cancer Res, 1989; 49(11)∶2988.
11. Kaye SB. The multidrug resistance phenotype [Ｊ]. Br J Cancer, 1988; 58(6)∶691.
12. Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicinselected variants of the human sarcoma cell line MESSA [Ｊ]. Cancer Res, 1985; 45(9)∶4091.
  1. 1. Shiraga K, Sakaguchi K, Senoh T, et al. Modulation of doxorubicin sensitivity by cyclosporine A in hepatocellular carcinoma cells and their doxorubicinresistant sublines [Ｊ]. J Gastroenterol Hepatol, 2001; 16(4)∶460.
  2. 2. 程國(guó)鈞, 李亞里, 田方， 等. 不同方式誘導(dǎo)人卵巢癌順鉑耐藥細(xì)胞株的比較 [Ｊ]. 中華腫瘤雜志, 2001; 23（4）∶305.
  3. 3. 陸家齊, 陸連榮, 蔣彥和, 等. PdGC81 人體胃底分化腺癌細(xì)胞系的建立及其生物學(xué)特征的觀察 [Ｊ]. 中華腫瘤雜志, 1986； 8（1）∶4.
  4. 4. 趙憲琪. 乳腺癌細(xì)胞系的建立與應(yīng)用研究 [Ｊ]. 實(shí)用腫瘤學(xué)雜志, 2001; 15（3）∶239.
  5. 5. Chauffert B, Martin M, Hammann A, et al. Amiodaroneinduced enhancement of doxorubicin and 4’deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo [Ｊ]. Cancer Res, 1986; 46(2)∶825.
  6. 6. Twentyman PR, Fox NE, Wright KA, et al. Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells [Ｊ]. Br J Cancer, 1986; 53(4)∶529.
  7. 7. 梁永鋸， 周肵熙， 潘啟超， 等. 肝癌體外藥敏感性試驗(yàn) [Ｊ]. 腫瘤, 2001; 21（1）∶17.
  8. 8. Flens MJ, Zaman GJ, van der Valk P, et al. Tissue distribution of the multidrug resistance protein [Ｊ]. Am J Pathol, 1996; 148(4)∶1237.
  9. 9. McGovern F, Kachel T, Vijan S, et al. Establishment and characterization of a doxorubicinresistant human bladder cancer cell line (MGHU1R) [Ｊ]. J Urol, 1988; 140(2)∶410.
  10. 10. Keizer HG, Schuurhuis GJ, Broxterman HJ, et al. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased Pglycoprotein expression in cultured SW1573 human lung tumor cells [Ｊ]. Cancer Res, 1989; 49(11)∶2988.
  11. 11. Kaye SB. The multidrug resistance phenotype [Ｊ]. Br J Cancer, 1988; 58(6)∶691.
  12. 12. Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicinselected variants of the human sarcoma cell line MESSA [Ｊ]. Cancer Res, 1985; 45(9)∶4091.